Trial Updates

Phase II study of ANX005 in patients with Huntington’s disease 3:49
Phase II study of ANX005 in patients with Huntington’s disease
Ann Morgan et al. • 16 Sep 2022
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease 1:43
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Phase II trial of SAGE-718 for the treatment of cognitive impairment in Huntington’s disease 2:52
Phase II trial of SAGE-718 for the treatment of cognitive impairment in Huntington’s disease
Aaron Koenig • 22 Sep 2022
IkT-148009 as a potential disease-modifying therapy in Parkinson’s disease 3:56
IkT-148009 as a potential disease-modifying therapy in Parkinson’s disease
Milton Werner • 16 Sep 2022
Update on Parkinson’s disease clinical trials 2:42
Update on Parkinson’s disease clinical trials
Margherita Fabbri • 17 Sep 2022
Update on OCEAN and OASIS: Opicapone for pain & sleep disorders in PD 1:32
Update on OCEAN and OASIS: Opicapone for pain & sleep disorders in PD
K. Ray-Chaudhuri • 17 Sep 2022
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD) 8:29
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD)
Christopher Morabito • 11 Apr 2022
COVID-19 and post-acute neurological sequelae 4:12
COVID-19 and post-acute neurological sequelae
Jennifer Frontera • 3 Apr 2022
Alternatives in HD treatment: RNA interference, small molecules, and combination approaches 5:14
Alternatives in HD treatment: RNA interference, small molecules, and combination approaches
Jee Bang • 4 Apr 2022
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab 1:12
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab
Lilyana Amezcua • 4 Apr 2022
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS 1:52
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS
Lawrence Steinman • 11 Apr 2022
EMTICS: The role of gene-environment interactions in the development of tics in pediatric patients 2:42
EMTICS: The role of gene-environment interactions in the development of tics in pediatric patients
Davide Martino • 3 Apr 2022
Phase II extension trial of CNM-Au8 in ALS 1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan • 4 Apr 2022
The pipeline of late-stage therapeutic options for patients with ALS 1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan • 4 Apr 2022
Direct oral anticoagulants after stroke: ongoing clinical trials 3:10
Direct oral anticoagulants after stroke: ongoing clinical trials
Edip Gurol • 2 Apr 2022
Vaginal estriol improves quality of life for patients with relapsing/remitting multiple sclerosis 3:03
Vaginal estriol improves quality of life for patients with relapsing/remitting multiple sclerosis
Mirla Avila • 12 Apr 2022
The content of VJNeurology is intended for healthcare professionals